|
| Primary information |
|---|
| ID | 13133 |
| Therapeutic ID | Th1385 |
| Protein Name | Technetium Tc-99m red blood cells |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours [FDA Label]. |
| Description | Technetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding. It is clinically useful in early detection and localization of bleeding sites, and preoperative diagnosis of hemangioma [A32178, A32179]. Autologous red blood cells are radiolabeled with sodium pertechnetate Tc 99m in the reaction vial. Radiolabeled red blood cells are re-injected intravenously into the patient for gamma scintigraphic imaging [FDA Label]. It is suggested that _in vitro_ labelling improves the heart-to-background ratio during imaging [A32181]. |
| Indication/Disease | Indicated for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding [FDA Label]. |
| Pharmacodynamics | Technetium Tc-99m red blood cells are diagnostic agents that are distributed within the circulation to assess the vascular nature of hemangiomas and diagnosis of venous occlusion [A32186]. Blood abnormalities can be detected during gamma scintigraphic imaging. |
| Mechanism of Action | Autologous red blood cells (RBC) are collected from the patient and put into the reaction vial for radiolabeling, followed by anticoagulation with heparin or Anticoagulant Citrate Dextrose Solution (ACD). In the reaction vial, stannous ion diffuses across the RBC membrane and accumulates intracellularly. Sodium hypochlorite, which does not cross the RBC membrane, is then added to the reaction vial to oxidize the extracellular stannous ion. Finally, sodium pertechnetate Tc 99m is added to the oxidized reaction vial to diffuse across the red blood cell membrane and be reduced by the intracellular stannous ion. Upon reduction, Tc 99m cannot diffuse out of the RBC. Technetium Tc 99m-labeled red blood cells are injected again into the patient for gamma scintigraphic imaging [FDA Label]. |
| Toxicity | No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility [FDA Label]. |
| Metabolism | NA |
| Absorption | NA |
| Following intravenous injection, the technetium Tc 99m-labeled red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of bodyweight [FDA Label]. |
| Clearance | NA |
| Categories | Radiopharmaceutical Activity |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |